{
  "scenario_id": "healthcare_genomics_gene_therapy_investment_implementation_2025",
  "context": "Global pharmaceutical company, 15000 employees, evaluating major investment in gene therapy platform for rare diseases",
  "stakeholders": {
    "requester": "VP Research & Development",
    "approvers": ["CEO", "CFO", "Chief Medical Officer", "Board of Directors"],
    "influencers": ["Head of Regulatory Affairs", "VP Commercial", "Patient Advocacy Groups", "Key Opinion Leaders"]
  },
  "request": {
    "amount": "$750M",
    "purpose": "Build integrated gene therapy platform including R&D, manufacturing, and commercialization capabilities",
    "urgency": "high",
    "justification": "Gene therapy represents transformative opportunity in rare disease treatment with $50B+ market potential and first-mover advantage"
  },
  "decision_process": [
    {
      "stage": "strategic_evaluation",
      "duration": "8 weeks",
      "activities": ["Market analysis", "Competitive landscape assessment", "Technology feasibility review"],
      "outcome": "Confirmed strong strategic fit with significant market opportunity"
    },
    {
      "stage": "technical_due_diligence",
      "duration": "6 weeks",
      "activities": ["Scientific validation", "IP landscape analysis", "Technical risk assessment"],
      "outcome": "Technology validated with manageable risks and strong IP position"
    },
    {
      "stage": "financial_modeling",
      "duration": "4 weeks",
      "activities": ["Cost-benefit analysis", "ROI projections", "Sensitivity analysis"],
      "outcome": "Projected 15% IRR with break-even in 7 years"
    },
    {
      "stage": "regulatory_pathway",
      "duration": "6 weeks",
      "activities": ["Regulatory strategy development", "Clinical trial design", "Approval pathway mapping"],
      "outcome": "Clear regulatory pathway with accelerated approval potential"
    },
    {
      "stage": "executive_review",
      "duration": "3 weeks",
      "activities": ["Board presentation", "Stakeholder alignment", "Final stakeholder alignment"],
      "outcome": "Approved with phased investment approach and key performance milestones"
    }
  ],
  "business_impact": {
    "financial_impact": "Expected $2B revenue contribution by 2030 with significant R&D tax credits",
    "market_position": "First-mover advantage in gene therapy with potential for 15% market share",
    "capability_building": "Advanced genomic medicine capabilities and specialized manufacturing expertise",
    "risk_factors": ["Clinical trial failures", "Regulatory delays", "Manufacturing scalability challenges", "Market adoption uncertainty"]
  },
  "decision_outcome": "Approved $750M investment with phased rollout: $300M initial platform development, $250M clinical programs, $200M manufacturing capabilities; additional $50M allocated for regulatory and market access strategies"
}